Shuwen Biotech Reports "Multi-Million Dollar" Investment from Tasly

00:04 EDT 17 Apr 2018 | ChinaBio Today

Shuwen Biotech, a Hangzhou diagnostics company, completed a A+ round that it described as an investment of "multi-million dollars" from Tasly Pharmaceutical Group. Shuwen aims to be the China diagnostic partner of choice for western diagnostic companies. So far, Shuwen has formed strategic partnerships with academic and commercial entities, resulting in exclusive licenses for over 20 first-in-class diagnostic technologies and 50+ patents in various medical specialties. More details....

Share this with colleagues:

Original Article: Shuwen Biotech Reports "Multi-Million Dollar" Investment from Tasly


More From BioPortfolio on "Shuwen Biotech Reports "Multi-Million Dollar" Investment from Tasly"

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.